| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/07/2004 | EP1404831A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/07/2004 | EP1404714A2 Nuclear hormone receptor ligand binding domain |
| 04/07/2004 | EP1404713A1 Novel keratinocyte growth factor-2 analogue in hair follicle |
| 04/07/2004 | EP1404710A2 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 04/07/2004 | EP1404706A2 Mycobacterial antigens expressed during latency |
| 04/07/2004 | EP1404705A1 Compositions and methods of using hiv vpr |
| 04/07/2004 | EP1404374A1 Slc2as as modifiers of the p53 pathway and methods of use |
| 04/07/2004 | EP1404365A2 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 04/07/2004 | EP1404359A2 Methods of treatment involving human mda-7 |
| 04/07/2004 | EP1404353A2 Methods of using a hyaluronan receptor |
| 04/07/2004 | EP1404350A2 Proteins associated with cell growth, differentiation, and death |
| 04/07/2004 | EP1404307A2 Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation |
| 04/07/2004 | EP1404298A2 A method for preparation of vesicles loaded with biological material and different uses thereof |
| 04/07/2004 | EP0712312B1 Suppression of inhibitors |
| 04/07/2004 | EP0559884B2 Viral recombinant vectors for expression in muscle cells |
| 04/07/2004 | CN1487999A Paramyxovirus vector encoding angiogenesis gene and utilization thereof |
| 04/07/2004 | CN1487953A Recepter in the EDb Fibronection domain |
| 04/07/2004 | CN1487841A Lentiviral vector-mediated gene transfer and uses thereof |
| 04/07/2004 | CN1487082A Depilation related gene and its application |
| 04/06/2004 | US6716974 Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| 04/06/2004 | US6716823 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 04/06/2004 | US6716627 Mucin 1, transmembrane may help to frustrate infection in the mammary gland (mastitis) and possibly in other sites in the body (such as bladder and kidney infections) by competitively inhibiting the binding of microorganisms |
| 04/06/2004 | US6716624 GSK3 polypeptides |
| 04/06/2004 | US6716623 Compositions and methods for identifying antigens which elicit an immune response |
| 04/06/2004 | US6716622 Tissue-specific self-inactivating gene therapy vector |
| 04/06/2004 | US6716600 Persephin and related growth factors |
| 04/06/2004 | US6716585 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis |
| 04/06/2004 | US6716575 Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| 04/06/2004 | CA2147372C Multidrug resistance gene |
| 04/06/2004 | CA2089563C Oligonucleotide modulation of cell adhesion |
| 04/06/2004 | CA2010321C Lymphocyte-associated cell surface protein |
| 04/02/2004 | WO2004031372A1 Insulin-secreting immortalized liver cell line modified by glucose sensitivity |
| 04/02/2004 | CA2435274A1 Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity |
| 04/01/2004 | WO2004027073A1 Modified adenoviral vectors for use in vaccines and gene therapy |
| 04/01/2004 | WO2004027049A2 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 04/01/2004 | WO2004027044A2 Triplex hairpin ribozyme |
| 04/01/2004 | WO2004027033A2 Lentiviral vector-mediated gene transfer and uses thereof |
| 04/01/2004 | WO2004026457A1 Process for producing microcapsule |
| 04/01/2004 | WO2004026453A2 Microcapsules and methods of use |
| 04/01/2004 | WO2004026343A1 Site-specific gene conversion promoter and gene therapeutic |
| 04/01/2004 | WO2004009123A3 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/01/2004 | WO2004007723A3 Genes |
| 04/01/2004 | WO2004005478A3 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 04/01/2004 | WO2004001032A3 Stable adenoviral vectors and methods for propagation thereof |
| 04/01/2004 | WO2003106630A3 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| 04/01/2004 | WO2003104402A3 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 04/01/2004 | WO2003102131A3 Nucleic acid mediated disruption of hiv fusogenic peptide interactions |
| 04/01/2004 | WO2003100436A3 Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (ccr10) |
| 04/01/2004 | WO2003099830A3 Cardiolipin compositions, methods of preparation and use |
| 04/01/2004 | WO2003099225A3 Compositions for delivering nucleic acids to cells |
| 04/01/2004 | WO2003097799A3 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS |
| 04/01/2004 | WO2003089609A3 Short fragment homologous replacement to provide bse resistant cattle |
| 04/01/2004 | WO2003087840A3 Protein involved in cancer |
| 04/01/2004 | WO2003084566A3 Proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003084540A3 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 04/01/2004 | WO2003082314A3 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 04/01/2004 | WO2003074078A3 Cg3842 homologous proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003072821A3 Method and nucleic acids for the analysis of a colon cell proliferactive disorder |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003063773A3 Differentially-regulated prostate cancer genes |
| 04/01/2004 | WO2003029429A3 Traversal of nucleic acid molecules through a fluid space and expression in repair cells |
| 04/01/2004 | WO2003029282A3 Tumor-peptide antigens from the human prdi-bf1-protein |
| 04/01/2004 | WO2003016563A3 Novel molecular target for neurotoxicity |
| 04/01/2004 | WO2002089856A8 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery |
| 04/01/2004 | WO2002083847A3 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2004 | WO2002077180A3 Novel nucleic acids and polypeptides |
| 04/01/2004 | WO2002070676A9 Use of protein histidine phosphatase |
| 04/01/2004 | US20040063922 Ester interchange; autocatalyst; genetic engineering; gene therapy for genetic disorders |
| 04/01/2004 | US20040063921 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/01/2004 | US20040063906 Peptide nucleic acid sequences; antibodies for controlling disease; bactericides, viricides |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063655 Antisense modulation of transforming growth factor-beta expression |
| 04/01/2004 | US20040063654 Attenuating expression of target gene in vivo; altering cell growth, survival and/or differentiation; stable respiratory formulation for pulmonary or nasal delivery |
| 04/01/2004 | US20040063652 Introducing multiple nucleic acid molecules simultaneously without deletereous effects; controlling level of expression |
| 04/01/2004 | US20040063632 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 04/01/2004 | US20040063618 Peptide nucleic acids having improved uptake and tissue distribution |
| 04/01/2004 | US20040063201 Controlling lineage development in an in vitro human tissue system for bone marrow transplantation |
| 04/01/2004 | US20040063131 Comprises neuroendocrine-specific proteins-like polypeptides (NSPLP) for diagnosis, prevention and treatment of neurodegenerative and cell proliferative diseases |
| 04/01/2004 | US20040063128 20 Human secreted proteins |
| 04/01/2004 | US20040063095 gM-negative EHV-mutants |
| 04/01/2004 | US20040062777 Genetic engineered polypeptides; enzyme inhibitors |
| 04/01/2004 | US20040062775 Nucleotide sequences; veterinary medicine; vaccine |
| 04/01/2004 | US20040062774 Multiple epitope immunoglobulin for prevention and/or treatment of mastitis; bactericides |
| 04/01/2004 | US20040062769 Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A |
| 04/01/2004 | US20040062761 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer |
| 04/01/2004 | US20040062756 Genetic engineering; hematopoietic or stem cells; binding lentivirus vector to cell surfaces |
| 04/01/2004 | US20040062752 Genetic engineered polynucleotide; antihemophilic factor; in situ administering to liver |
| 04/01/2004 | US20040062750 Use of mullerian inhibiting substance for treating excess androgen states |
| 04/01/2004 | US20040062749 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | CA2499996A1 Triplex hairpin ribozyme |
| 04/01/2004 | CA2499643A1 Lentiviral vector-mediated gene transfer and uses thereof |
| 04/01/2004 | CA2499385A1 Modified adenoviral vectors for use in vaccines and gene therapy |
| 04/01/2004 | CA2499066A1 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 03/31/2004 | EP1403374A1 Gene transfer into primate emborynic stem cells using vsv-g-pseudotype simian immunodeficiency virus vector |
| 03/31/2004 | EP1403372A2 Composition and methods for the treatment and diagnosis of cardiovascular disease |
| 03/31/2004 | EP1403284A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION |
| 03/31/2004 | EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 03/31/2004 | EP1402902A1 Method for treatment of vascular regeneration |